The ongoing De-Escalation of Breast Radiation (DEBRA) trial is looking at omitting radiation therapy after lumpectomy in low-risk, hormone receptor-positive, HER2-negative, early-stage breast cancer [50]. This evidence concerns the gene ERBB2 and breast cancer.